Compare BYND & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | PYXS |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.6M | 243.5M |
| IPO Year | 2019 | 2021 |
| Metric | BYND | PYXS |
|---|---|---|
| Price | $1.22 | $4.21 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $1.70 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 104.5M | 797.0K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $290,565,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.83 |
| 52 Week High | $7.69 | $5.55 |
| Indicator | BYND | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 48.86 |
| Support Level | $1.15 | $3.67 |
| Resistance Level | $1.48 | $4.61 |
| Average True Range (ATR) | 0.16 | 0.45 |
| MACD | 0.07 | -0.13 |
| Stochastic Oscillator | 61.94 | 29.79 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.